Table of Content


Chapter 1   Methodology and Scope
1.1    Market scope and definitions
1.2    Research design
1.2.1    Research approach
1.2.2    Data collection methods
1.3    Base estimates and calculations
1.3.1    Base year calculation
1.3.2    Key trends for market estimation
1.4    Forecast model
1.5    Primary research and validation
1.5.1    Primary sources
1.5.2    Data mining sources
Chapter 2   Executive Summary
2.1    Industry 360? synopsis
Chapter 3   Industry Insights
3.1    Industry ecosystem analysis
3.2    Industry impact forces
3.2.1    Growth drivers
3.2.1.1    Growing cases of cancer malignancies across population
3.2.1.2    Rising inclination towards targeted treatment
3.2.1.3    Robust product pipeline with regulatory approvals across geographies
3.2.2    Industry pitfalls and challenges
3.2.2.1    High drug cost impedes the market growth
3.2.2.2    Side-effects of CAR T-cell therapy
3.3    Growth potential analysis
3.4    Regulatory landscape
3.5    Technological landscape
3.6    Future market trends
3.7    Gap analysis
3.8    Porter’s analysis
3.9    PESTEL analysis
Chapter 4   Competitive Landscape, 2024
4.1    Introduction
4.2    Company market share analysis
4.3    Company matrix analysis
4.4    Competitive analysis of major market players
4.5    Competitive positioning matrix
4.6    Strategy dashboard
Chapter 5   Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)
5.1    Key trends
5.2    Abecma (idecabtagene vicleucel)
5.3    Breyanzi (lisocabtagene maraleucel)
5.4    Carvykti (ciltacabtagene autoleucel)
5.5    Kymriah (tisagenlecleucel)
5.6    Tecartus (brexucabtagene autoleucel)
5.7    Yescarta (axicabtagene ciloleucel)
5.8    Other products
Chapter 6   Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)
6.1    Key trends
6.2    Leukemia
6.3    Lymphoma
6.4    Multiple myeloma
6.5    Other indications
Chapter 7   Market Estimates and Forecast, By Demographic, 2021 – 2034 ($ Mn)
7.1    Key trends
7.2    Adults
7.3    Pediatric
Chapter 8   Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)
8.1    Key trends
8.2    Hospitals
8.3    Cancer treatment centers
8.4    Specialty clinics
Chapter 9   Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
9.1    Key trends
9.2    North America
9.2.1    U.S.
9.2.2    Canada
9.3    Europe
9.3.1    Germany
9.3.2    UK
9.3.3    France
9.3.4    Spain
9.3.5    Italy
9.3.6    Netherlands
9.4    Asia Pacific
9.4.1    China
9.4.2    Japan
9.4.3    India
9.4.4    Australia
9.4.5    South Korea
9.5    Latin America
9.5.1    Brazil
9.5.2    Mexico
9.5.3    Argentina
9.6    Middle East and Africa
9.6.1    South Africa
9.6.2    Saudi Arabia
9.6.3    UAE
Chapter 10   Company Profiles
10.1    Allogene Therapeutics
10.2    Autolus Therapeutics
10.3    bluebird bio
10.4    Bristol-Myers Squibb Company
10.5    CRISPR Therapeutics
10.6    Gilead Sciences
10.7    GSK plc.
10.8    ImmunoAct
10.9    Johnson & Johnson
10.10    JW Therapeutics (Shanghai)
10.11    Medigene AG
10.12    Merck KGaA
10.13    Novartis AG
10.14    Sangamo Therapeutics
10.15    Sorrento Therapeutics